CoMind DuoSense: Developing a new standard-of-care for monitoring the injured brain

今天，即使在世界上最先进、资金最充足的医院里，医生也无法直接测量人体最脆弱、最重要的器官：大脑。可用的临床工具仅限于那些高度侵入性的（例如在头部钻孔），高度不准确的（例如脑血氧测量方法），或两者兼而有之。在CoMind，我们开发了一种新形式的大脑监测技术。我们的技术已经在医疗器械开发过程中，我们的第一个产品的临床试验将于2023年底开始。在这个项目中，我们将把我们世界领先的技术带到一个全新的方向，并为CoMind的技术已经提供的关键临床信号添加一个新的维度。通过重新配置我们的技术并进行有针对性的临床试验，该项目将使我们的技术能够测量所有最关键的神经学参数之一的准确和绝对测量：脑血流量。脑血流量（或 ** 脑血流量 **，CBF）对大脑健康至关重要：流量太少，大脑缺氧，太多，大脑患脑肿胀和中风的风险增加。管理患者的CBF是重症监护和麻醉期间患者预后的关键，但目前还没有技术允许医生在床边连续测量CBF。该项目将基于CoMind最近的创新，创建一个新的原型技术。我们将在实验室的健康志愿者中测试和验证这个原型，然后将这个原型部署到临床环境中，作为有针对性的临床试验的一部分。一旦完成，我们将把该项目中取得的进展整合到我们现有的产品开发途径中，以实现一种全新的多参数神经监测设备，该设备能够测量几种关键的神经生理信号，包括绝对脑血流量。该设备将对从重症监护室到手术室的众多患者群体产生直接而深远的影响。该项目的成功将使CoMind能够确保更多的患者和医生尽快获得这项技术，改善患者的治疗效果、生活质量和国家医疗保健系统的效率。

Today, even in the most sophisticated and well-funded hospitals in the world, doctors have no direct measures of the most vulnerable, vital organ in the body: the brain. The clinical tools available are limited to those that are either highly invasive (e.g. drilling a hole in the head), highly inaccurate (e.g. cerebral oximetry methods), or both.At CoMind, we have developed a novel form of brain monitoring technology. Our technology is already in the medical device development process, with clinical trials of our first product due to begin in late 2023\.In this project, we will take our world-leading technology in a whole new direction, and add a new dimension to the critical clinical signals that CoMind's technology can already provide. By re-configuring our technology and undertaking a targeted clinical trial, this project will enable our technology to measure accurate and **absolute** measures of one of the most critical neurological parameters of all: brain blood flow. Brain blood flow (or **Cerebral Blood Flow**, CBF) is critical to brain health: too little flow and the brain suffers from a lack of oxygen, too much and the brain is at increased risk of brain swelling and stroke. Managing a patient's CBF is key to patient outcomes in intensive care and during anaesthesia, but there is currently no technology that permits doctors to measure CBF continuously at the bedside.This project will build on the recent innovations made at CoMind to create a new prototype technology. We will test and validate this prototype in healthy volunteers in the laboratory and then deploy this prototype into the clinical environment as part of a targeted clinical trial. Once complete, we will integrate the advances made in this project into our existing product development pathway to achieve a completely novel multi-parameter neuromonitoring device capable of measuring several critical neurophysiological signals including absolute Cerebral Blood Flow. This device will have an immediate and far-reaching impact across numerous patient groups, from the intensive care unit, to the operating theatre. The success of this project will allow CoMind to ensure more patients and doctors have access to this technology as soon as possible, improving patient outcomes, quality-of-life, and the efficacy of our National Healthcare System.